Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diaplasinin SCHEMBL30320322 | 0.88 | PLA2G4A (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Diaplasinin SCHEMBL4024262 | 0.88 | PLA2G4A (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4023545 | 0.88 | TUBB4A (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4021086 | 0.87 | PTPN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3854572 | 0.84 | PPARG (0.42) | HPGDALDH1A1HSD17B10PPARGHSD11B1 | |
| SCHEMBL4025900 | 0.83 | ALOX5AP (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4024279 | 0.81 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6579684 | 0.80 | PTPN1 (0.38) | — | |
| SCHEMBL4023365 | 0.79 | HSD11B1 (0.34) | HPGDALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4022525 | 0.76 | PTPN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | claimed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | claimed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | claimed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | claimed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | claimed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | claimed |
| US-7629377-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1397356-B1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7351730-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2007092207-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-08-09 | — | — | US | disclosed |
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| US-6939886-B2 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | WYETH | 2004-12-30 | — | — | US | disclosed |
| US-6800654-B2 | FOR TREATING CONDITIONS RESULTING FROM FIBRINOLYTIC DISORDERS SUCH AS DEEP VEIN THROMBOSIS AND CORONARY HEART DISEASE, AND PULMONARY FIBROSIS. | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185186-A1 | COMPOSITIONS FOR THE DELIVERY OF SUBSTITUTED NAPTHYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | INMT, AANAT, NAPEPLD | PSEN1 298/4885PSEN2 220/4885APH1B 3680/4885 |
| US-20060014725-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, F12 | PSEN1 3586/4885PSEN2 4477/4885APH1B 3535/4885 |
| US-20080182883-A1 | SUBSTITUTED NAPHTHYL INDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | TFPI, SERPINE1, F12 | PSEN1 3420/4885PSEN2 4336/4885APH1B 3384/4885 |
| US-20030032626-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PSEN1 3324/4885PSEN2 4221/4885APH1B 4036/4885 |
| US-20040266733-A1 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) | TFPI, SERPINE1, SERPINC1 | PSEN1 3232/4885PSEN2 4172/4885APH1B 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.